| Thomas A Warr, MD | |
|
3000 15th Ave S, Great Falls, MT 59405-5240 | |
| (406) 454-2171 | |
| (406) 771-3082 |
| Full Name | Thomas A Warr |
|---|---|
| Gender | Male |
| Speciality | Medical Oncology |
| Experience | 43 Years |
| Location | 3000 15th Ave S, Great Falls, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356342208 | NPI | - | NPPES |
| 0073424 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 6376 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Highland Hospice | Butte, MT | Hospice |
| Great Falls Clinic Hospital | Great falls, MT | Hospital |
| Benefis Hospitals Inc | Great falls, MT | Hospital |
| Pondera Medical Center | Conrad, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Great Falls Clinic Llc | 8325944499 | 58 |
News Archive
"The increasing incidence of depression is a major health problem and Mental Health Week is an opportunity to highlight the range of services and new treatment options available to these people still suffering."
Diamond Light Source (Diamond) has been contributing heavily to the global effort to understand and combat COVID-19.
Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).
Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.
› Verified 5 days ago
| Entity Name | Great Falls Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801897780 PECOS PAC ID: 8325944499 Enrollment ID: O20031209001107 |
News Archive
"The increasing incidence of depression is a major health problem and Mental Health Week is an opportunity to highlight the range of services and new treatment options available to these people still suffering."
Diamond Light Source (Diamond) has been contributing heavily to the global effort to understand and combat COVID-19.
Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).
Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas A Warr, MD 3000 15th Ave S, Great Falls, MT 59405-5240 Ph: (406) 454-2171 | Thomas A Warr, MD 3000 15th Ave S, Great Falls, MT 59405-5240 Ph: (406) 454-2171 |
News Archive
"The increasing incidence of depression is a major health problem and Mental Health Week is an opportunity to highlight the range of services and new treatment options available to these people still suffering."
Diamond Light Source (Diamond) has been contributing heavily to the global effort to understand and combat COVID-19.
Halozyme Therapeutics, Inc. and Intrexon Corporation, today announced the signing of a worldwide exclusive licensing agreement for the use of rHuPH20 in the development of a subcutaneous injectable formulation of Intrexon Corporation's recombinant human alpha 1-antitrypsin (rHuA1AT).
Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.
› Verified 5 days ago
Edmund J Brennan, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1101 26th St S, Great Falls, MT 59405 Phone: 406-731-8888 | |
David E Anderson, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1917 4th St S, Great Falls, MT 59405 Phone: 406-453-7570 Fax: 406-771-3021 | |
Steven P Akre, MD Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1400 29th St S, Great Falls, MT 59405 Phone: 406-454-2171 Fax: 406-771-3021 | |
Mr. Donald Hall Berdeaux, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1117 29th St S, Great Falls, MT 59405 Phone: 406-731-8200 Fax: 406-731-8178 | |
Paul Fredrick Schmook, RPSGT Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1917 4th St S, Great Falls, MT 59405 Phone: 406-453-7570 | |
Dr. Kirsten Elizabeth Krauss, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1417 9th St S Ste 200, Great Falls, MT 59405 Phone: 406-454-8070 Fax: 406-454-8072 | |
Bradford A Bergman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1401 25th St S, Great Falls, MT 59405 Phone: 406-731-8888 Fax: 406-731-8876 |